Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - Cabaletta Bio reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Cabaletta Bio announced earnings per share of $-0.390 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.470 on revenue of $0.00.
Cabaletta Bio 's are down 4.96% and is trading at $2.020 , still down 85.11% from its 52 week high of $13.57 set on Friday, November 19, 2021.
Cabaletta Bio shares gained 4.12% to trade at $2.020 in intra-day trade the report.
Cabaletta Bio follows other major Healthcare sector earnings this month
Cabaletta Bio's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar